3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Multiple Sclerosis
2
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Multiple Sclerosis, Relapsing-Remitting
1
Melanoma
1
Lymphopenia
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Nivolumab
13
Ipilimumab
10
pembrolizumab
8
cemiplimab
6
Surveys and Questionnaires
6
Biopsy
6
aldesleukin
5
Radiotherapy
5
Interleukin-2
5
Blood Specimen Collection
5
Temozolomide
4
Sirolimus
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Fluorouracil
4
Educational Status
4
Cyclophosphamide
4
sonidegib
3
fludarabine phosphate
3
fludarabine
3
avelumab
3
Vemurafenib
3
Surgical Procedures, Operative
3
Radiation
3
Petrolatum
3
Cetuximab
3
Aminolevulinic Acid
3
trametinib
2
dabrafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Skin Neoplasms
×
Fingolimod Hydrochloride
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled